Journal ID (nlm-ta): PLoS One
Journal ID (iso-abbrev): PLoS ONE
Journal ID (publisher-id): plos
Journal ID (pmc): plosone
Title:
PLoS ONE
Publisher:
Public Library of Science
(San Francisco, CA USA
)
ISSN
(Electronic):
1932-6203
Publication date
(Electronic):
10
June
2015
Publication date Collection: 2015
Volume: 10
Issue: 6
Electronic Location Identifier: e0125103
Affiliations
[1
]Arkin Mental Health and Addiction Treatment Centre, Amsterdam, the Netherlands
[2
]Department of Psychiatry and Neuropsychology, South Limburg Mental Health Research
and Teaching Network, EURON, Maastricht University, Maastricht, the Netherlands
[3
]Department of psychiatry, Erasmus University Medical Center, Erasmus University, Rotterdam,
the Netherlands
[4
]Department of psychiatry, University Medical Centre Groningen, University of Groningen,
Groningen, the Netherlands
[5
]Academic Medical Centre University of Amsterdam, Department of Psychiatry, Amsterdam,
The Netherlands
Author notes
Competing Interests: Jansen-Cilag, Eli Lilly and Company, Astra-Zeneca and Lundbeck provided unrestricted
grants for analysis. There are no patents, products in development or marketed products
to declare. This does not alter the authors' adherence to all the PLOS ONE policies
on sharing data and materials.
Conceived and designed the experiments: FVD MS RS IG LDH. Performed the experiments:
IG LDH. Analyzed the data: FVD MS SR IG LDH. Wrote the paper: FVD MS RS IG LDH.
¶ Membership of the Genetic Risk and Outcome of Psychosis (GROUP) Investigators is
provided in the Acknowledgments.
Article
Publisher ID:
PONE-D-15-04569
DOI: 10.1371/journal.pone.0125103
PMC ID: 4465647
PubMed ID: 26061170
SO-VID: f4cd228f-c990-40dd-aba4-e00f747f3a6d
Copyright statement:
Copyright @
2015
License:
This is an open access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided
the original author and source are credited
This work was supported by the Geestkracht program of the Dutch Health Research Council
(ZON-MW, grant number 10-000-1002) and matching funds from participating universities
and mental health care organizations (Site Amsterdam: Academic Psychiatric Centre
AMC, Ingeest, Arkin, Dijk en Duin, Rivierduinen, Erasmus MC, GGZ Noord Holland Noord;
Site Utrecht: University Medical Centre Utrecht, Altrecht, Symfora, Meerkanten, Riagg
Amersfoort, Delta; Site Groningen: University Medical Centre Groningen, Lentis, GGZ
Friesland,GGZ Drenthe, Dimence, Mediant, GGZ De Grote Rivieren and Parnassia psycho-medical
centre; Site Maastricht: Maastricht University Medical Centre, GGZ Eindhoven, GGZ
Midden-Brabant, GGZ Oost-Brabant, GGZ Noord- Midden Limburg, Mondriaan Zorggroep,
Prins Clauscentrum Sittard, RIAGG Roermond, Universitair Centrum Sint-Jozef Kortenberg,
CAPRI University of Antwerp, PC Ziekeren Sint-Truiden, PZ Sancta Maria Sint-Truiden,
GGZ Overpelt, OPZ Rekem). The analyses were supported by unrestricted grants from
Jansen-Cilag, Eli Lilly and Company, Astra-Zeneca and Lundbeck. The research leading
to these results has received funding from the European Community's Seventh Framework
Program under grant agreement No. HEALTH-F2-2009-241909 (Project EU-GEI). The funders
had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.